Gilead Sciences, Inc. $GILD Shares Bought by Whitaker Myers Wealth Managers LTD.

Whitaker Myers Wealth Managers LTD. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,284 shares of the biopharmaceutical company’s stock after purchasing an additional 3,890 shares during the period. Whitaker Myers Wealth Managers LTD.’s holdings in Gilead Sciences were worth $2,310,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Aviva PLC increased its position in shares of Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after buying an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd acquired a new position in shares of Gilead Sciences during the 4th quarter worth $1,418,000. NBC Securities Inc. boosted its position in shares of Gilead Sciences by 150.3% in the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Gilead Sciences by 43.9% in the 4th quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company’s stock worth $6,973,000 after buying an additional 17,325 shares in the last quarter. Finally, Flputnam Investment Management Co. grew its stake in Gilead Sciences by 66.5% in the 4th quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock valued at $12,978,000 after acquiring an additional 42,243 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. Citigroup raised their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Truist Financial lowered their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Finally, HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead raised its 2026 base-business outlook, citing continued strength in its HIV portfolio and growing PrEP demand. Management also highlighted Trodelvy growth and two potential product launches in the second half of the year. GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
• Positive Sentiment: Second-quarter revenue of $7.80 billion exceeded expectations, and revenue increased 10.6% year over year. Although reported earnings were distorted by acquisition-related items, the underlying operating performance was viewed as stronger than the headline loss suggests. Gilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss
• Positive Sentiment: Analysts at Cantor Fitzgerald and Needham & Company reiterated favorable views, assigning Gilead Overweight and Buy ratings, respectively. Gilead Sciences Earns Overweight Rating from Cantor Fitzgerald Gilead Sciences Earns Buy Rating from Needham
• Neutral Sentiment: Gilead’s research pipeline could provide longer-term growth, but investors are weighing whether development spending and potential launches can translate into sustainable commercial returns. Can Gilead Sciences Turn Research Into Growth?
• Neutral Sentiment: RBC raised its Gilead price target to $123, signaling a more constructive view, though the target remains below the reference market price and therefore offers limited near-term upside. RBC Increases Gilead Sciences Price Target
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lackluster interim data, weakening expectations for a major combination-therapy expansion of Trodelvy. MSD and Gilead scrap Phase III Trodelvy-Keytruda study

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 82,000 shares of company stock valued at $10,641,790. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 1.8%

Shares of GILD stock opened at $133.21 on Friday. The firm has a 50-day moving average price of $129.41 and a 200 day moving average price of $136.20. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a market capitalization of $165.39 billion, a price-to-earnings ratio of -49.89 and a beta of 0.32. The company has a current ratio of 1.14, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the prior year, the firm earned $2.01 EPS. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post -0.5 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.